A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants
Key facts
- Who runs it
- Ionis Pharmaceuticals, Inc.
- Where
- Birmingham, Dallas, Fort Worth, Kansas City, San Francisco, and Tacoma, United StatesSee the 6 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 12 people, planned
- Started
- 31 Jul 2026
- Expected to end
- Aug 2031
- Type of study
- Interventional, 2 groups
- Treatments tested
- Olezarsen
- Record updated
- 2 November 2026
Who can take part
- Age
- 2 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Parental or legally authorized representative consent must be obtained, and the participants must provide age-appropriate or cognition-appropriate assent, as determined by the Investigator. The parent or legal guardian must be able to understand and comply with the study visit schedule and all other study procedures
- Must be able to comply with all study procedures
- Age 12 to less than 18 years at the time of informed consent/assent (Cohort 1); age 2 to less than 12 years at time of informed consent/assent (Cohort 2)
- Willing to fast for at least 10 hours before visits requiring fasted blood sampling
- A diagnosis of Familial Chylomicronemia Syndrome (type 1 Hyperlipoproteinemia) by documentation of confirmed homozygote, compound heterozygote or double heterozygote for loss-of-function mutations in type 1-causing genes
- Fasting TGs ≥880 mg/dL at screening. If fasting TG is < 880 mg/dL, up to two additional tests may be performed during the screening period with any single test used to qualify
Who cannot take part
- Major surgery within 3 months of screening
- Plasma apheresis within 4 weeks prior to screening or planned during the study
- Treatment with another investigational drug, biological agent, or device within one month of screening, or 5 half-lives of investigational agent, whichever is longer
- Active pancreatitis within 4 weeks prior to screening or during the screening period
- Malignancy diagnosed or treated within 5 years prior to screening or during the screening period; Note: Other protocol-specified inclusion/exclusion criteria may apply
- History of bleeding, diathesis, or coagulopathy
- Diabetes mellitus with any of the following:; Newly diagnosed within 12 weeks prior to screening or during the screening period; Hemoglobin A1c (HbA1c) ≥9.5% at screening; Change in basal insulin regimen >20% within 3 months prior to screening or during the screening period; Type 1 diabetes
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 2 and 17 years old?
This trial is currently available in United States.
- University of AlabamaBirmingham, United StatesContact: Ionis Pharmaceuticals, Inc.Taking people
- University of Texas Southwestern Medical CenterDallas, United StatesContact: Ionis Pharmaceuticals, Inc.Taking people
- Cook Children's Medical CenterFort Worth, United StatesContact: Ionis Pharmaceuticals, Inc.Taking people
- Children's Mercy HospitalKansas City, United StatesContact: Ionis Pharmaceuticals, Inc.Taking people
- UCSF Benioff Children's HospitalSan Francisco, United StatesContact: Ionis Pharmaceuticals, Inc.Taking people
- Mary Bridge Children'sTacoma, United StatesContact: Ionis Pharmaceuticals, Inc.Taking people
About the trial
What the trial wants to find out
The primary purpose of the study is to evaluate the efficacy of olezarsen administered by subcutaneous injection to pediatric participants with FCS.
The 2 groups in the trial
- Cohort 1Treatment being tested
Participants aged 12 to \<18 years will receive multiple doses of olezarsen, at a dose level that depends on body weight, once every month by subcutaneous injection for up to 1 year. All participants may continue to the optional 1-year long-term extension period with the last dose received being after 2 years of treatment.
Treatment: Olezarsen
- Cohort 2Treatment being tested
Participants aged 2 to \<12 years will receive multiple doses of olezarsen, at a dose level based on information obtained from Cohort 1, once every month by subcutaneous injection for up to 1 year. All participants may continue to the optional 1-year long-term extension period with the last dose received being after 2 years of treatment.
Treatment: Olezarsen
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-Label Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Pediatric Patients With Familial Chylomicronemia Syndrome (FCS)
- Criteria questions
- Built from NCT07727538, who can take part
- Record updated
- 2 November 2026